Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
24-26 February, 2026
Global ChemShowGlobal ChemShow
Not Confirmed
Not Confirmed
19-20 December, 2025
BIO Partnering at JPMBIO Partnering at JPM
Not Confirmed
Not Confirmed
12-15 January, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Tides Asia
Not Confirmed
Contact SupplierTides Asia
Industry Trade Show
Not Confirmed
24-26 February, 2026
Global ChemShowGlobal ChemShow
Industry Trade Show
Not Confirmed
19-20 December, 2025
BIO Partnering at JPMBIO Partnering at JPM
Industry Trade Show
Not Confirmed
12-15 January, 2026
Digital content
NEWS #PharmaBuzz
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761094
11 Oct 2023
// ECONOMIC TIMES
https://www.indianpharmapost.com/news/eni-and-dompe-farmaceutici-join-forces-for-health-research-14773
10 Oct 2023
// BUSINESSWIRE
30 Nov 2022
// PRNEWSWIRE
https://www.prnewswire.com/news-releases/dompe-new-published-data-point-to-spike-protein-interactions-with-estrogen-receptors-as-a-cause-for-coagulopathy-in-covid-19-patients-signaling-sex-effects-and-a-path-to-improved-vaccines-301690590.html
26 Jul 2022
// PRNEWSWIRE
https://www.prnewswire.com/news-releases/two-clinical-studies-to-treat-mild-to-moderate-covid-19-at-home-reveal-value-of-exscalate-dompes-ai-platform-for-drug-design-301592560.html
13 Jun 2022
// PRNEWSWIRE
https://www.prnewswire.com/news-releases/dompe-announces-results-of-phase-2-study-evaluating-the-efficacy-and-safety-of-reparixin-in-patients-with-severe-covid-19-pneumonia-301566589.html
Drugs in Development
Details:
The collaboration aims to combine strengths of Eurofins Discovery’s DiscoveryOne comprehensive Integrated Drug Discovery capabilities with Dompé’s powerful supercomputing AI platform.
Lead Product(s): Undisclosed,Inapplicable
Therapeutic Area: Technology Brand Name: Undisclosed
Study Phase: Discovery PlatformProduct Type: Undisclosed
Recipient: Eurofins Discovery
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 10, 2024
Lead Product(s) : Undisclosed,Inapplicable
Therapeutic Area : Technology
Highest Development Status : Discovery Platform
Recipient : Eurofins Discovery
Deal Size : Undisclosed
Deal Type : Collaboration
Eurofins Discovery Extends AI-powered Integrated Drug Discovery Collaboration
Details : The collaboration aims to combine strengths of Eurofins Discovery’s DiscoveryOne comprehensive Integrated Drug Discovery capabilities with Dompé’s powerful supercomputing AI platform.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 10, 2024
Details:
Cenegermin is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Neurotrophic Keratitis.
Lead Product(s): Cenegermin,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Protein
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 13, 2024
Lead Product(s) : Cenegermin,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cenegermin is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Neurotrophic Keratitis.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
May 13, 2024
Details:
Recombinant Human Nerve Growth Factor is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dry Eye Syndromes.
Lead Product(s): Recombinant Human Nerve Growth Factor,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Protein
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 06, 2024
Lead Product(s) : Recombinant Human Nerve Growth Factor,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Recombinant Human Nerve Growth Factor is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dry Eye Syndromes.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
February 06, 2024
Details:
Reparixin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Primary Myelofibrosis.
Lead Product(s): Reparixin,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Recipient: Icahn School of Medicine at Mount Sinai
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 28, 2023
Details : Reparixin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Primary Myelofibrosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 28, 2023
Details:
Cenegermin is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Corneal Diseases.
Lead Product(s): Cenegermin,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Protein
Recipient: Tufts Medical Center
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 26, 2023
Lead Product(s) : Cenegermin,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Recipient : Tufts Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
NGF Treatment for Patients With Neuropathic Corneal Pain
Details : Cenegermin is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Corneal Diseases.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
January 26, 2023
Details:
A197, novel, first-in-class, topical immunomodulatory agent for treatment of dry eye disease. Primary endpoint of trial measures change from baseline in corneal fluorescein staining with key secondary endpoint evaluating eye dryness symptoms using VAS.
Lead Product(s): A197,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Recipient: Aramis Biosciences
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 03, 2022
Lead Product(s) : A197,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Recipient : Aramis Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : A197, novel, first-in-class, topical immunomodulatory agent for treatment of dry eye disease. Primary endpoint of trial measures change from baseline in corneal fluorescein staining with key secondary endpoint evaluating eye dryness symptoms using VAS.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 03, 2022
Details:
Reparixin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Respiratory Distress Syndrome.
Lead Product(s): Reparixin,Inapplicable
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 11, 2022
Lead Product(s) : Reparixin,Inapplicable
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Add-on Reparixin in Adult Patients With ARDS
Details : Reparixin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Respiratory Distress Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 11, 2022
Details:
Two papers, published in The Lancet and Nature, indicate that treatment with oral raloxifene, a selective estrogen receptor modulator (SERM) with a proven safety profile, may be efficacious against SARS-CoV-2 clinically relevant variants.
Lead Product(s): Raloxifene Hydrochloride,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 26, 2022
Lead Product(s) : Raloxifene Hydrochloride,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Two Clinical Studies to Treat Mild-to-Moderate COVID-19 at Home Reveal Value of Exscalate, Dompé'...
Details : Two papers, published in The Lancet and Nature, indicate that treatment with oral raloxifene, a selective estrogen receptor modulator (SERM) with a proven safety profile, may be efficacious against SARS-CoV-2 clinically relevant variants.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 26, 2022
Details:
In hospitalized patients with COVID-19 Pneumonia, the rates of clinical events among those treated with Reparixin (n=36) were statistically significantly lower than standard of care (n=19).
Lead Product(s): Reparixin,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 13, 2022
Lead Product(s) : Reparixin,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Dompé Announces Results of Phase 2 Study Evaluating the Efficacy and Safety of Reparixin in Patie...
Details : In hospitalized patients with COVID-19 Pneumonia, the rates of clinical events among those treated with Reparixin (n=36) were statistically significantly lower than standard of care (n=19).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 13, 2022
Details:
Ladarixin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetes Mellitus, Type 1.
Lead Product(s): Ladarixin,Inapplicable
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 10, 2022
Lead Product(s) : Ladarixin,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinical Trial on Ladarixin Adjunctive Therapy to Improve Glycemic Control in Type 1 Diabetes.
Details : Ladarixin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetes Mellitus, Type 1.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 10, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
Share 
